18 August 2026 : Original article
Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients With Posttransplant Lymphoproliferative Disorder: A Single-Center Retrospective Study
Ying Liu ABCDEFG 1,2,3,4,5, Ru-Zhou Cai
ABCDEF 2,3,4,5,6, Wei Qu ACDE 2,3,4,5,6, Lin Wei ADE 2,3,4,5,6, Zhi-Gui Zeng ADE 2,3,4,5,6, Zhi-Jun Zhu ACDE 2,3,4,5,6, Li-Ying Sun ABCDEFG 2,3,4,5,7*
DOI: 10.12659/AOT.952021
Ann Transplant 2026; 31:e952021
Table 1 Baseline characteristics of the patients.
| Case | Sex | Age at LT (months) | Primary disease | Donor type | Donor age (years) | ABO blood type (recipient/donor) | Time from transplantation to PTLD (months) | IS regimen at PTLD onset | Tacrolimus trough level (μg/L) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | 8 | BA | Living donor | 29 | B/B | 32 | Tacrolimus 0.625 mg q12h | 4.3 |
| 2 | Female | 7 | BA | Living donor | 36 | B/O | 11 | Tacrolimus 0.25 mg q12h | 7.2 |
| 3 | Female | 5 | BA | Living donor | 31 | A/A | 9 | Tacrolimus 0.5 mg q12h | 7.1 |
| 4 | Male | 14 | BA | DCD | 1 | A/A | 27 | Tacrolimus 1 mg q12h | 1.3 |
| 5 | Male | 19 | Cryptogenic cirrhosis | Living donor | 32 | AB/AB | 11 | Tacrolimus 0.375 mg q12h | 1.1 |
| 6 | Female | 5 | BA | Living donor | 39 | A/A | 13 | Tacrolimus 0.75 mg q12h | 1.1 |
| BA – biliary atresia; DCD – donation-after-circulatory-death; IS – immunosuppression; LT – liver transplantation; PTLD – post-transplant lymphoproliferative disorder. | |||||||||